ReviewAbdominal radiology (New York)2026
Diagnostic performance of liver imaging reporting and data system ancillary features for hepatocellular carcinoma: a systematic review and evidence synthesis.
Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically review and evaluate the evidence supporting the role of Liver Imaging Reporting and Data System (LI-RADS) ancillary features (AFs) in optimizing hepatocellular carcinoma (HCC) diagnosis across magnetic resonance imaging (MRI), computed tomography (CT), and contrast-enhanced ultrasound (CEUS) modalities, with a focus on their incremental value in specific clinical scenarios.
methodsA comprehensive literature search was performed across PubMed and Embase from 2011 to 2024 to identify studies on LI-RADS AFs. Significant ancillary features (SAFs)-a review-specific descriptive framework rather than an official LI-RADS category-were defined as features demonstrating a statistically significant contribution to HCC diagnosis or LI-RADS diagnostic performance in at least one included study (p < 0.05).
resultsA total of 101 articles were included. In terms of imaging modality distribution, MRI was predominant (91.1%, 92/101), while CT (21.8%, 22/101) and CEUS (9.9%, 10/101) studies were relatively limited. For LI-RADS categories LR-1 to LR-5, fourteen SAFs were identified on MRI (e.g., hepatobiliary phase hypointensity, diffusion restriction). For lesions ≤ 3 cm, the incremental value of applying a single guideline-recommended AF was marginal. In contrast, applying combinations of ≥ 4 AFs significantly improved sensitivity by 10.6-18.3% without a significant loss of specificity. Evidence for CT-based AFs was limited and inconsistent. For CEUS LR-1 to LR-5 observations, six AFs were identified, with exploratory markers showing potential incremental value, whereas the two official AFs showed inconsistent performance. For LR-M lesions, 14 SAFs significantly contributed to differentiating HCC from other hepatic malignancies (p < 0.05). In treatment response assessment (TRA), five SAFs-two of which are guideline-recommended-improved diagnostic sensitivity by 3.2-42.8% without loss of specificity.
conclusionLI-RADS AFs enhance HCC diagnostic accuracy when complementing major features, with the most robust evidence supporting MRI-based AFs. In contrast, AFs based on CT and CEUS require further validation.
Indexed as
Identifiers
42720760What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.